Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CA3 | P07451 | 2/20 | 0.31 |
| ▸ | CA5A | P35218 | 2/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.31 |
| ▸ | PAM | P19021 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14157935 | 0.77 | CA2 (0.50) | ALDH1A1CA2POLBSMN1; SMN2MEN1 | |
| SCHEMBL7142955 | 0.71 | CA2 (0.40) | ALDH1A1CA2POLBSMN1; SMN2MEN1 | |
| SCHEMBL16330338 | 0.69 | CA2 (0.42) | ALDH1A1CA2POLBSMN1; SMN2MEN1 | |
| SCHEMBL5485794 | 0.69 | CA2 (0.42) | ALDH1A1CA2POLBSMN1; SMN2MEN1 | |
| SCHEMBL21754091 | 0.66 | — | — | |
| SCHEMBL6202148 | 0.66 | ALDH1A1 (0.55) | ALDH1A1CYP2D6ALOX15PAM | |
| SCHEMBL19170305 | 0.65 | CA2 (0.34) | ALDH1A1CA2POLBSMN1; SMN2 | |
| SCHEMBL3134391 | 0.65 | CYP2D6 (1.00) | ALDH1A1CYP2D6ALOX15PAM | |
| SCHEMBL190067 | 0.65 | CYP2D6 (1.00) | ALDH1A1CYP2D6ALOX15PAM | |
| SCHEMBL213024 | 0.65 | CYP2D6 (1.00) | ALDH1A1CYP2D6ALOX15PAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363640-B1 | NUCLEIC ACID DERIVATIVES | BIO RAD LABORATORIES (US) | 2010-04-28 | — | — | EP | disclosed |
| US-7683164-B2 | Nucleic acid derivatives | BIO-RAD LABORATORIES INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20090005334-A1 | cyclic moieties which enable the formation of stable hybrids with natural nucleic acids and can therefore be efficiently used in a wide variety of applications and, in particular, in antisense therapy | BIO-RAD LABORATORIES INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-7348148-B2 | Nucleic acid derivatives | BIO-RAD LABORATORIES INC. (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1363640-A4 | NUCLEIC ACID DERIVATIVES | BIO RAD LABORATORIES (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20060148751-A1 | Nucleic acid derivatives | BIO-RAD LABORATORIES INC. (US) | 2006-07-06 | — | — | US | disclosed |
| US-7034131-B2 | Nucleic acid derivatives | BIO-RAD LABORATORIES INC. (US) | 2006-04-25 | — | — | US | disclosed |
| EP-1363640-A2 | NUCLEIC ACID DERIVATIVES | BIO-RAD LABORATORIES, INC. (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030191074-A1 | Nucleic acid derivatives | BIO-RAD LABORATORIES INC. | 2003-10-09 | — | — | US | disclosed |
| WO-2002061110-A2 | NUCLEIC ACID DERIVATIVES | BIO-RAD LABORATORIES, INC. (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191074-A1 | Nucleic acid derivatives | NSUN2, POLRMT, ADAR | ALDH1A1 2425/4885CYP2D6 4480/4885ALOX15 4744/4885 |
| US-20060148751-A1 | Nucleic acid derivatives | NSUN2, POLRMT, ADAR | ALDH1A1 2503/4885CYP2D6 4509/4885ALOX15 4741/4885 |
| US-20090005334-A1 | cyclic moieties which enable the formation of stable hybrids with natural nucleic acids and can therefore be efficiently used in a wide variety of applications and, in particular, in antisense therapy | POLRMT, NSUN2, RNGTT | ALDH1A1 2920/4885CYP2D6 3963/4885ALOX15 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.